These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 34019887)

  • 1. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer.
    van Weelden WJ; Lalisang RI; Bulten J; Lindemann K; van Beekhuizen HJ; Trum H; Boll D; Werner HMJ; van Lonkhuijzen LRCW; Yigit R; Forsse D; Witteveen PO; Galaal K; van Ginkel A; Bignotti E; Weinberger V; Sweegers S; Kroep JR; Cabrera S; Snijders MPLM; Inda MA; Eriksson AGZ; ; Krakstad C; Romano A; van de Stolpe A; Pijnenborg JMA
    Am J Obstet Gynecol; 2021 Oct; 225(4):407.e1-407.e16. PubMed ID: 34019887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis.
    Nishio S; Shimokawa M; Tasaki K; Nasu H; Yoshimitsu T; Matsukuma K; Terada A; Tsuda N; Kawano K; Ushijima K
    Gynecol Oncol; 2018 Sep; 150(3):432-437. PubMed ID: 30037491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study.
    Zaino RJ; Brady WE; Todd W; Leslie K; Fischer EG; Horowitz NS; Mannel RS; Walker JL; Ivanovic M; Duska LR
    Int J Gynecol Pathol; 2014 Nov; 33(6):543-53. PubMed ID: 25272292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
    van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
    Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study.
    Covens AL; Filiaci V; Gersell D; Lutman CV; Bonebrake A; Lee YC
    Gynecol Oncol; 2011 Feb; 120(2):185-8. PubMed ID: 21075433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
    Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
    Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer.
    Yang YC; Wu CC; Chen CP; Chang CL; Wang KL
    Gynecol Oncol; 2005 Nov; 99(2):287-93. PubMed ID: 16051341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
    Eskander RN; Ali S; Dellinger T; Lankes HA; Randall LM; Ramirez NC; Monk BJ; Walker JL; Eisenhauer E; Hoang BH
    Int J Gynecol Cancer; 2016 Jan; 26(1):125-32. PubMed ID: 26397159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.
    Gadducci A; Cosio S; Genazzani AR
    Crit Rev Oncol Hematol; 2006 Jun; 58(3):242-56. PubMed ID: 16436330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
    Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
    PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
    Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
    Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation and nuclear localization of beta-catenin in endometrial carcinoma in response to progesterone therapy.
    Saegusa M; Hamano M; Kuwata T; Yoshida T; Hashimura M; Akino F; Watanabe J; Kuramoto H; Okayasu I
    Cancer Sci; 2003 Jan; 94(1):103-11. PubMed ID: 12708483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.
    Westin SN; Fellman B; Sun CC; Broaddus RR; Woodall ML; Pal N; Urbauer DL; Ramondetta LM; Schmeler KM; Soliman PT; Fleming ND; Burzawa JK; Nick AM; Milbourne AM; Yuan Y; Lu KH; Bodurka DC; Coleman RL; Yates MS
    Am J Obstet Gynecol; 2021 Feb; 224(2):191.e1-191.e15. PubMed ID: 32805208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
    Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X
    J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
    Reyes HD; Carlson MJ; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Yang S; Stephan JM; Savage EC; Dai D; Goodheart MJ; Leslie KK
    Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.
    Thigpen JT; Brady MF; Alvarez RD; Adelson MD; Homesley HD; Manetta A; Soper JT; Given FT
    J Clin Oncol; 1999 Jun; 17(6):1736-44. PubMed ID: 10561210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus.
    Bonneterre J; Hutt E; Bosq J; Graham JD; Powell MA; Leblanc E; Fujiwara K; Herzog TJ; Coleman RL; Clarke CL; Gilles EM; Zukiwski AA; Monk BJ
    Gynecol Oncol; 2015 Sep; 138(3):663-7. PubMed ID: 26142884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-1 system and sex steroid receptor gene expression in human endometrial cancer.
    Singer CF; Kronsteiner N; Marton E; Walter I; Kubista M; Czerwenka K; Schreiber M; Tschugguel W; Wieser F; Kubista E
    Gynecol Oncol; 2002 Jun; 85(3):423-30. PubMed ID: 12051868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer.
    Andres S; Finch L; Iasonos A; Zhou Q; Girshman J; Chhetri-Long R; Green H; Jang D; O'Cearbhaill R; Kyi C; Cohen S; Friedman C; Makker V; Chi DS; Sonoda Y; Chiang S; Aghajanian C; Weigelt B; Grisham RN
    Gynecol Oncol; 2024 Oct; 189():30-36. PubMed ID: 38991472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution in endometrial cancer: evidence from an immunohistochemical study.
    Vandenput I; Trovik J; Leunen K; Wik E; Stefansson I; Akslen L; Moerman P; Vergote I; Salvesen H; Amant F
    Int J Gynecol Cancer; 2011 Feb; 21(2):316-22. PubMed ID: 21734474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.